Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Holdings (COSM) has commenced efforts toward a direct listing on the Nasdaq Capital Markets. On September 15, 2021, the Board approved a private offering of 5,000,000 shares of Series A Preferred Stock to a private investor for $5 million. Shareholders holding 51% of voting power approved the Offering on December 17, 2021. The Series A Preferred Stock is convertible into common stock at $4.00 or 80% of the average VWAP prior to uplisting, with a floor at $3.00. This move aims to enhance liquidity and expand the company's market presence.
Cosmos Holdings (OTCQX: COSM) reported its third quarter financial results for 2021, highlighting positive adjusted net income and EBITDA. The company focused on debt reduction, converting $10.2 million of debt to equity, and secured an investment commitment of approximately $5.5 million from Ault Global Holdings. Cosmos expanded its distribution network, entering an exclusive agreement in Germany and Austria and launching products on Alibaba's Tmall Global. Working capital rose to $6.9 million, and shareholder equity increased to $4.7 million, showcasing financial improvement.
Cosmos Holdings (COSM) has successfully integrated SSI SCHAEFER's A-Frame Automated Robotic Picking System into its logistics center, CosmoFarm, enhancing order processing capabilities. This system can manage up to 40,000 products per hour and is designed to handle various packaging shapes and sizes. CEO Greg Siokas emphasized that this automation supports the company’s growth ambitions by improving service quality and productivity. CosmoFarm, based in Athens, Greece, is licensed for wholesale pharmaceutical distribution, serving over 1,130 pharmacies.
Cosmos Holdings (COSM) announced receiving initial bridge financing totaling approximately $500,000 and an additional $5 million in Series A Preferred Stock, pending Nasdaq listing approval. This funding from Ault Global Holdings supports Cosmos's expansion efforts and its strategic plans for trading on Nasdaq. CEO Greg Siokas expressed gratitude for the investment, highlighting its potential to accelerate global distribution and e-commerce strategies.
Cosmos Holdings has secured initial bridge financing of approximately $500,000 and is set to receive an additional $5 million in Series A Preferred Stock upon the approval of its Nasdaq listing. This investment comes from Ault Global Holdings and aims to accelerate Cosmos's growth and expansion in the pharmaceutical market. Cosmos plans to expand its distribution network and enhance its e-commerce strategy. The company is focused on its proprietary line of nutraceuticals and pharmaceuticals, aiming to improve patient outcomes.
Cosmos Holdings (COSM) announced a debt exchange agreement to reduce its total debt. The Company will issue 321,300 shares at $5.00 per share, allowing the conversion of EUR $1.35 million debt (approx. US $1.60 million). Following this, an additional EUR $1.00 million (approx. US $1.19 million) will convert upon Nasdaq approval for 238,000 shares. This reduces the remaining debt to EUR $350,000 (approx. US $414,000). CEO Greg Siokas expressed optimism about the debt reduction and ongoing business expansion across various markets.
Cosmos Holdings (COSM) reported strong growth in its second quarter of 2021, achieving 15.8% year-over-year revenue increase and 27.8% sequential growth. The company has expanded its distribution network with a significant agreement with Mediprovita for its nutraceuticals in Germany and Austria, alongside a three-year deal with REMAI to launch products on Alibaba’s Tmall Global. However, Cosmos experienced a temporary decline in margins, and reported a net loss of $2.38 million. The company is focused on debt reduction, with $5.25 million converted to equity, and aims to uplist to Nasdaq.
Cosmos Holdings (COSM) has partnered with REMAI, a leading Chinese e-commerce solutions provider, to launch its Sky Premium Life nutraceutical products on Tmall Global. This three-year distribution agreement positions REMAI to handle marketing, customer service, logistics, and distribution in China. The initial branding and test marketing phase will commence in Q4 2021, with profit-sharing anticipated as sales ramp up in 2022. Analysts predict China will dominate the global nutraceutical market by 2030, with Tmall Global being a critical platform for foreign brands.
Cosmos Holdings (COSM) announced the conversion of $1.25 million in debt, bringing total conversions to $4 million this year. The conversion, executed by CEO Greg Siokas, exchanged related party debt for 208,333 shares at $6.00 each, above market price. This action aims to enhance cash flow and facilitate business scaling and distribution expansion across Europe, Asia, and North America. The company remains committed to uplisting to the Nasdaq Capital Market and executing initiatives to boost shareholder value.
Cosmos Holdings, Inc. (OTCQX: COSM) announced a further reduction of $1.0 million in related party debt, converting it into 166,667 shares of common stock at $6.00 per share. This transaction follows a previous debt reduction of $3.0 million at the same price. CEO Greg Siokas emphasized the conversion strengthens their balance sheet and supports the company's growth and potential uplisting to the Nasdaq. Cosmos specializes in pharmaceuticals and has a broad EU distribution network, aiming to enhance patient outcomes.